Clinical trial

A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC

NCT04672369

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2021-06-06

PhasePHASE1

Study timeline

Study start (actual)2021-06-06Date precision: day

Registry last updated2023-06-22

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Advanced Lung Cancerunresolved

Interventions

IBI939BIOLOGICAL

SintilimabBIOLOGICAL

Sponsors & collaborators

Innovent Biologics (Suzhou) Co. Ltd.lead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04672369 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.